tradmap

NRXS Neuraxis, INC

$6.63 -0.45%

Data as of close

Healthcare · Electromedical & Electrotherapeutic Apparatus

Neuraxis, INC (NRXS) is a healthcare company in the Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $83 million. Shares last traded at $6.63, 28.5% below their 52-week high. Over the past year the stock is up 139.5%. Net profit margin is -144.4%, below the peer median of -10.0%. Revenue grew 32.9% year over year.

Market Cap
$83M
Shares Out
12.6M
EPS (TTM)
-$0.77
P/E (TTM)*
—
P/S Ratio
15.67
P/B Ratio
12.37
Dividend / Share
—
Dividend Yield
—
52-Week High
$9.28
52-Week Low
$2.25
Volume (venue)
498
Avg Vol (3m, venue)
3,020.27

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-10.70%
1M
-7.78%
3M
-2.93%
6M
-23.38%
YTD
+47.12%
1Y
+139.53%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
39.98
SMA (50)
$6.88
SMA (200)
$6.69
Price vs SMA50
-3.52%
Price vs SMA200
-0.85%
ATR (14)
$0.36

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$5M
Net Income
-$8M
Gross Margin
85.6%
Operating Margin
-144.5%
Net Margin
-144.4%
Return on Equity
-114.0%
Return on Assets
-76.8%
Current Ratio
3.04
Debt / Equity
0.03
Revenue Growth (YoY)
+32.9%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$0.19 2026-08-11
Q1 2026 -$0.18 2026-05-12
Q4 2025 (derived) -$0.16 2026-03-19
FY 2025 -$0.95 2026-03-19
Q3 2025 -$0.24 2025-11-10
Q2 2025 -$0.22 2025-08-12

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Electromedical & Electrotherapeutic Apparatus peers

NRXS vs 14 industry peers (Electromedical & Electrotherapeutic Apparatus), by market cap. Data as of close

P/S vs peers
15.67 / 2.62 med
+498% premium
Net margin vs peers
-144.4% / -10.0% med
below median
1–14 of 14
MDTMedtronic$126.5B24.183.3713.9%-0.41%
LIVNLivanova Plc$4.4B23.403.0012.8%-0.17%
ITGRInteger Holdings Corp$4.3B41.512.365.7%+0.03%
AXGNAxogen, Inc.$3.0B—11.08-12.0%-0.68%
TMDXTransmedics Group, Inc.$2.3B15.413.5022.7%+1.32%
CNMDConmed Corp$1.4B29.961.033.4%+1.60%
CBLLCeribell, Inc.$1.1B—10.11-68.0%+4.91%
INMDInmode Ltd.$893M9.512.4125.3%+2.92%
CVCapsoVision, Inc$335M———-0.74%
ELMDElectromed, Inc.$224M19.853.0415.3%+0.02%
FOCLEDAP TMS SA$162M—2.29-41.5%+0.35%
VANIVivani Medical, Inc.$96M—201.30—-3.20%
STXSStereotaxis, Inc.$85M—2.83-74.2%-3.42%
NRXSNeuraxis, INC$83M———-0.45%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.